Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Innovative Approaches for Targeted Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies.

NCT00149019 is registered in ClinicalTrials.gov with Hadassah Medical Organization as lead sponsor.

NCT NCT00149019
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00149019 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Innovative Approaches for Targeted Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies.
Lead sponsor
Hadassah Medical Organization
Phase
Phase 2
Overall status
Withdrawn
Start date
May 31, 2002
Completion date
September 30, 2005
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic solid tumors